EA202092539A1 - NLRP3 MODULATORS - Google Patents

NLRP3 MODULATORS

Info

Publication number
EA202092539A1
EA202092539A1 EA202092539A EA202092539A EA202092539A1 EA 202092539 A1 EA202092539 A1 EA 202092539A1 EA 202092539 A EA202092539 A EA 202092539A EA 202092539 A EA202092539 A EA 202092539A EA 202092539 A1 EA202092539 A1 EA 202092539A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nlrp3 modulators
nlrp3
modulators
compounds
medicaments
Prior art date
Application number
EA202092539A
Other languages
Russian (ru)
Inventor
Йонг Чжанг
Ашвиникумар В. Гавай
Эндрю Ф. Доннел
Шомир Гхош
Уильям Р. Роуш
Прасанна Сивапракасам
Стивен П. Зейтц
Джей А. Маркволдер
Original Assignee
Иннэйт Тьюмор Иммунити, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иннэйт Тьюмор Иммунити, Инк. filed Critical Иннэйт Тьюмор Иммунити, Инк.
Priority claimed from PCT/US2019/028823 external-priority patent/WO2019209896A1/en
Publication of EA202092539A1 publication Critical patent/EA202092539A1/en

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение обеспечивает соединения формулы (I)где все переменные являются такими, как определено в настоящем документе. Эти соединения являются модуляторами NLRP3, которые можно применять в качестве лекарственных средств для лечения пролиферативных нарушений, таких как рак, у субъекта (например, человека).The present invention provides compounds of formula (I) wherein all variables are as defined herein. These compounds are NLRP3 modulators that can be used as medicaments for the treatment of proliferative disorders, such as cancer, in a subject (eg, a human).

EA202092539A 2019-03-28 2019-04-24 NLRP3 MODULATORS EA202092539A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825044P 2019-03-28 2019-03-28
PCT/US2019/028823 WO2019209896A1 (en) 2018-04-25 2019-04-24 Nlrp3 modulators

Publications (1)

Publication Number Publication Date
EA202092539A1 true EA202092539A1 (en) 2021-02-16

Family

ID=74855483

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092539A EA202092539A1 (en) 2019-03-28 2019-04-24 NLRP3 MODULATORS

Country Status (1)

Country Link
EA (1) EA202092539A1 (en)

Similar Documents

Publication Publication Date Title
MX2020011234A (en) Nlrp3 modulators.
EA202091491A1 (en) NEW BENZYLAMINE SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS
NZ761519A (en) Nlrp3 modulators
WO2018022668A3 (en) Neuromodulating compositions and related therapeutic methods for the treatment of cancer
PH12019501097A1 (en) Magl inhibitors
NZ750174A (en) Somatostatin modulators and uses thereof
PH12019501102A1 (en) Magl inhibitors
PH12020551934A1 (en) Magl inhibitors
PH12019502646A1 (en) Pyrazole magl inhibitors
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
EA201990400A1 (en) COMPOUNDS AND COMPOSITIONS AND THEIR APPLICATION
TR201900148T4 (en) 2,4 diamino-quinoline substituted as novel agents against cancer.
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
PH12019502693A1 (en) Heteroaromatic compounds as vanin inhibitors
PH12021551280A1 (en) Heteroaromatic compounds as vanin inhibitors
MX2021006489A (en) Heteroaromatic compounds as vanin inhibitors.
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
CL2019002583A1 (en) Dual inhibitors of magl and faah.
MX2021006490A (en) Heteroaromatic compounds as vanin inhibitors.
EA202092539A1 (en) NLRP3 MODULATORS
EA202090283A1 (en) NLRP3 MODULATORS